Department of Internal Medicine, Allegheny General Hospital, Pittsburgh, PA, United States.
Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA, United States.
Int J Cardiol. 2020 Nov 15;319:131-138. doi: 10.1016/j.ijcard.2020.06.036. Epub 2020 Jun 27.
Pulmonary arterial hypertension (PAH) is associated with a significant burden of morbidity and mortality. We examined national trends in PAH-related hospitalizations, associated inpatient mortality (IM), length of stay (LOS) and hospitalization charges from 2007 to 2016, as well as predictors of IM and LOS in this population.
We used the National Inpatient Sample to identify PAH admissions using International classification of diseases (ICD) codes 416.0 (ICD-9) and I27.0 (ICD-10). Records suggestive of secondary causes of pulmonary hypertension were excluded. 6162 (weighted) records with PAH as the primary diagnosis were analyzed.
Mean age was 38.7 years, with the majority being females (78.8%). Overall IM was 6.03%, mean LOS 7.6 ± 0.5 days and mean charges $84,100 ± 6200. PAH-related hospitalizations (per million) (27 in 2007 vs. 28 in 2016, p = 0.19) and associated IM (4.5% in 2007 vs. 6.8% in 2016, p = 0.748) as well as LOS (5.9 days in 2007 vs 6.7 days in 2016, p = 0.304) remained unchanged over the decade. Charges increased by 2.4-fold ($43,800 in 2007 to $103,300 in 2016, p = 0.002). While right heart failure, fluid/electrolyte disorders, cardiac arrhythmia and neurological disorders were associated with increased IM, Hispanic race was found to have a survival benefit. Fluid/electrolyte disorders and coagulopathy were associated with increased LOS.
Despite significant advancements in PAH therapies over the duration of this study, the rate of PAH hospitalizations, and associated IM and LOS remain unchanged. The study identified the predictors of IM and prolonged LOS in PAH population which could be used for additional risk stratification of these patients.
肺动脉高压(PAH)与发病率和死亡率的显著负担有关。我们研究了 2007 年至 2016 年期间与 PAH 相关的住院治疗、相关住院死亡率(IM)、住院时间(LOS)和住院费用的国家趋势,以及该人群中 IM 和 LOS 的预测因素。
我们使用国家住院患者样本,使用国际疾病分类(ICD)第 416.0 条(ICD-9)和 I27.0 条(ICD-10)识别 PAH 入院病例。排除提示肺动脉高压继发性原因的记录。分析了 6162 条(加权)以 PAH 为主要诊断的记录。
平均年龄为 38.7 岁,大多数为女性(78.8%)。总体 IM 为 6.03%,平均 LOS 为 7.6 ± 0.5 天,平均费用为 84100 ± 6200 美元。PAH 相关住院治疗(每百万)(2007 年为 27 例,2016 年为 28 例,p=0.19)和相关 IM(2007 年为 4.5%,2016 年为 6.8%,p=0.748)以及 LOS(2007 年为 5.9 天,2016 年为 6.7 天,p=0.304)在这十年中保持不变。费用增加了 2.4 倍(2007 年为 43800 美元,2016 年为 103300 美元,p=0.002)。虽然右心衰竭、液体/电解质紊乱、心律失常和神经系统疾病与 IM 增加有关,但发现西班牙裔种族具有生存优势。液体/电解质紊乱和凝血障碍与 LOS 延长有关。
尽管在这项研究期间 PAH 治疗取得了重大进展,但 PAH 住院治疗率以及相关的 IM 和 LOS 仍然保持不变。该研究确定了 PAH 人群中 IM 和延长 LOS 的预测因素,可用于对这些患者进行额外的风险分层。